ASTHMA CONTROL EVALUATION (ACE): A BIOMARKER-BASED APPROACH TO IMPROVING ASTHMA

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。居住在低收入市中心社区的哮喘儿童和青少年是高危人群，其特点是与哮喘相关的发病率和死亡率增加。在这一人群中，有重要的需要找到改善长期哮喘控制的策略。呼出的一氧化氮(ENO)是支气管炎的标志，在哮喘失控期间似乎增加，在哮喘药物治疗期间下降。公司最近开始销售测量eNO的设备，作为监测和加强哮喘控制的一种手段，但尚未有随机临床试验解决这种监测是否改善哮喘结果的问题。这项研究的目的是确定与单纯根据临床参数选择治疗相比，根据eNO测量结合临床参数选择哮喘治疗是否能改善哮喘控制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Asthmatic children and adolescents living in low-income, inner-city communities are a high-risk population characterized by increased asthma-related morbidity and mortality. There is an important need to find strategies for improving long term asthma control in this population. Exhaled nitric oxide (eNO), a marker of bronchial inflammation, appears to be increased during periods of uncontrolled asthma and decreased during treatment with medicines for asthma. Companies have recently started to market equipment to measure eNO as a means of monitoring and enhancing asthma control, but no randomized clinical trial has yet addressed the question of whether such monitoring improves asthma outcomes. The purpose of this study is to determine whether selection of asthma therapy on the basis of eNO measurements combined with clinical parameters improves asthma control compared with therapy chosen solely on the basis of clinical parameters.